Conference Attendance Announcement – BioEurope 2023

Conference Attendance Announcement – BioEurope 2023

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending Europe’s Flagship Partnering Event for the Life Sciences Industry, BioEurope 2023 in Munich, Germany on November 6-8th.


Physiomics’ Chief Operating Officer, Dr Pete Sargent and Head of Business Development, Hayley Close will be attending the event. The aim is to engage with leaders from across the BioPharma industry to explore opportunities for collaboration that can benefit from the Company’s breadth of experience in mathematical modelling, simulation and biostatistics.


If you are interested in meeting at BioEurope, please contact us through the Partnering System or email Hayley directly at


We look forward to seeing you there!



Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980


Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341


Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494




Notes to Editor


About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.